Mode
Text Size
Log in / Sign up
Phase 2 N=36 Randomized Single-blind Treatment

Evaluation of a Test Mouthwash and Dentifrice Regimen in an In-situ Model of Dental Erosion

Tooth Erosion

Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Apr 2013
Primary outcome: Primary: Adjusted Mean Percent Net Erosion Resistance (NER) of Enamel Specimens Exposed to Test Dentifrice + Test MR Relative to: 1) Test Dentifrice+ Sterile Water Rinse 2) Reference Dentifrice+ Sterile Water Rinse 3) Placebo Dentifrice+ Sterile Water Rinse — -2.88; -14.54; -29.48; -40.05 Percent NER — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Sodium fluoride (Drug); Sodium monoflurophosphate (Drug); Sterile water (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
GlaxoSmithKline
Primary completion
Oct 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Adjusted Mean Percent Net Erosion Resistance (NER) of Enamel Specimens Exposed to Test Dentifrice + Test MR Relative to: 1) Test Dentifrice+ Sterile Water Rinse 2) Reference Dentifrice+ Sterile Water Rinse 3) Placebo Dentifrice+ Sterile Water Rinse
-2.88; -14.54; -29.48; -40.05 <0.0001 sig
SECONDARY
Adjusted Mean Percentage Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to Test Dentifrice + Test MR Relative to: 1)Test Dentifrice+Sterile Water Rinse 2)Reference Dentifrice+Sterile Water Rinse 3)Placebo Dentifrice+ Sterile Water Rinse
42.14; 38.02; 30.88; 30.57 0.0083 sig

Summary

An in situ model will be used to evaluate and compare enamel remineralization of bovine enamel specimens.

Eligibility Criteria

Inclusion Criteria

  • An intact maxillary dental arch suitable for the retention of the palatal appliance and an intact mandibular dental arch - subjects may have fixed bridges replacing missing teeth
  • No current active caries or periodontal disease that may compromise the study or the health of the subjects
  • A gum base stimulated whole saliva flow rate greater than or equal to 0.8 mL/minute and an unstimulated whole saliva flow rate greater than or equal to 0.2 mL/minute

Exclusion Criteria

  • Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01128972). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search